Skip to main content
CANN GROUP LIMITED logo

CANN GROUP LIMITED — Investor Relations & Filings

Ticker · CAN ISIN · AU000000CAN2 LEI · 529900XX42XELLXVQE42 ASX Manufacturing
Open in API
Filings indexed 729 across all filing types
Latest filing 2021-03-09 Regulatory Filings
Country AU Australia
Listing ASX CAN

About CANN GROUP LIMITED

https://www.canngrouplimited.com/

Cann Group Limited specializes in the cultivation, manufacture, and supply of medicinal cannabis products. The company focuses on providing pharmaceutical-grade cannabis for therapeutic use, utilizing advanced greenhouse technology and automated cultivation systems to ensure standardized quality and consistency. Its operations encompass the entire supply chain, from plant genetics and breeding to the production of finished medicinal products, including oils and dried flower. Cann Group serves healthcare professionals and patients through established distribution channels and maintains a focus on research and development to advance cannabinoid-based treatments. The company leverages large-scale production capabilities to meet growing demand in both domestic and international medicinal markets, emphasizing rigorous quality control and compliance with international pharmaceutical standards.

Recent filings

Filing Released Lang Actions
Appendix 2A - Issue of shares for Satipharm acquisition 15 pages 302.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and references to previous announcements such as Appendix 3B. This type of document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document is a formal regulatory filing to the exchange about securities quotation, which fits best under the category of Regulatory Filings (RNS).
2021-03-09 English
Cann completes acquisition of Satipharm business 4 pages 235.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 10 March 2021 regarding the completion of an acquisition by Cann Group Limited of the Satipharm business. It details the terms of the acquisition, including share issuance and deferred consideration arrangements. The content focuses on a corporate transaction (acquisition) and financing details related to the issuance of shares as consideration. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report or Interim Report. It is not a regulatory certification or voting result announcement. The document is clearly an update on a capital transaction and financing activity related to the acquisition and share issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2021-03-09 English
Cann supplies medicinal cannabis for clinical trial 2 pages 628.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 March 2021 from Cann Group Limited about supplying medicinal cannabis for a clinical trial. It describes the trial phases, collaborators, and product details. There are no financial statements, regulatory certifications, or detailed financial data. The document is a corporate announcement about a clinical trial partnership and product supply, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a general company announcement about a business development. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2021-03-08 English
Half Yearly Report and Accounts 24 pages 10.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Financial Report - 31 December 2020' and includes detailed financial data, Directors' Report, consolidated financial statements, and an independent auditor's review report. It covers the half-year period ending 31 December 2020, with comprehensive financial results, operational review, funding details, and management changes. The presence of actual financial statements and substantive financial analysis confirms it is a financial report for a period shorter than a full fiscal year. The document is approximately 15,000 characters long, indicating it is the full report rather than a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-02-21 English
Cann releases half-year results - 31 December 2020 3 pages 204.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 22 February 2021, titled 'Cann Group releases half year results for 6 months to 31 December 2020'. It contains detailed financial results for the half year period ending 31 December 2020, including revenue, operating loss, operational updates, capital raising, acquisitions, and strategic investments. The document includes substantive financial data and analysis for a period shorter than a full fiscal year (half year). It is not merely an announcement of a report or a certification, but a comprehensive interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-02-21 English
Cann Group - Half yearly investor presentation 18 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Half year results presentation February 2021' and contains detailed financial data for the first half of fiscal year 2021, including revenue, EBITDA, loss after tax, and EPS. It also discusses operational summaries, strategic M&A activity, updated revenue guidance, and outlook for the second half of FY21. The content is structured as a presentation with forward-looking statements, financial results, strategic updates, and Q&A sections. The presence of detailed financial figures and operational commentary for a half-year period indicates this is a comprehensive interim or quarterly report rather than a brief earnings release or an announcement. The document is a presentation format but contains substantive financial data and analysis for a half-year period, fitting the definition of an Interim / Quarterly Report (IR). H1 2021
2021-02-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.